Fasting apolipoprotein B48 is a marker for peripheral arterial disease in type 2 diabetes

• Published in: Acta diabetologica 2013-06, Vol.50 (3), p.383-389
• Main Authors: Mancera-Romero, J., Sánchez-Chaparro, M. A., Rioja, J., Ariza, M. J., Olivecrona, G., González-Santos, P., Valdivielso, P.
• Format: Article
• Language: English
• Subjects: Aged; Ankle Brachial Index; Apolipoprotein B-48 - blood; Apolipoprotein B48; Apolipoproteins E - genetics; Biomarkers; Biomarkers - blood; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Angiopathies - drug therapy; Diabetic Angiopathies - metabolism; Fasting; Female; Genotype; Humans; Hypoglycemic Agents - therapeutic use; Hypolipidemic Agents - therapeutic use; Insulin - therapeutic use; Internal Medicine; Lipoprotein Lipase - blood; LPL mass; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Original Article; Peripheral arterial disease; Peripheral Arterial Disease - drug therapy; Peripheral Arterial Disease - etiology; Peripheral Arterial Disease - metabolism; Proteins; Type 2 diabetes
• ISSN: 0940-5429; 1432-5233; 1432-5233
• DOI: 10.1007/s00592-012-0434-x

An earlier study showed that fasting and postprandial concentrations of apolipoprotein B48 were raised in patients with type 2 diabetes (DM2) and peripheral arterial disease (PAD) as compared with persons without DM2 or persons with DM2 but not PAD. The aim of this study was to confirm the association of PAD and B48 in a larger group of patients with DM2 and the relation of B48 with the preheparin lipoprotein lipase (LPL) mass. We studied 456 patients with DM2. PAD was defined as an ankle-brachial index (ABI)